Randomized Phase II Study of Dasatinib vs Placebo in Addition to Exemestane in Advanced ER/PR-Positive Breast Cancer [BMS CA180-261 Study].

Authors
Category Primary study
JournalCANCER RESEARCH
Year 2011
This article has no abstract
Epistemonikos ID: d9578e0be59bd54d5e881fe2a454b38f225d1596
First added on: Feb 05, 2025